Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1583 - Prognostic factors in patients with uterine leiomyosarcoma: A multi‑institutional retrospective study from the Japanese Gynecologic Oncology Group

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Sarcoma

Presenters

Kazuhiro Takehara

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

K. Takehara1, N. Yamashita2, T. Motohashi3, K. Harano4, T. Nakanishi5, H. Tokunaga6, N. Susumu7, Y. Ueda8, Y. Yokoyama9, Y. Watanabe5, R. Watanabe10, N. Teramoto11, H. Tsuda12, T. Saito13

Author affiliations

  • 1 Gynecologic Oncology, Shikoku Cancer Center, 791-0280 - Matusyama/JP
  • 2 Clinical research Center, Shikoku Cancer Center, Matsuyama/JP
  • 3 Obstetrics And Gynecology, Kuwana City Hospital, 543 - Kuwana/JP
  • 4 Breast Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 5 Obstetrics And Gynecology, Tohoku Medical and Pharmaceutical University, Sendai/JP
  • 6 Obstetrics And Gynecology, Tohoku University Graduate School of Medicine, Sendai/JP
  • 7 Obstetrics And Gynecology, International University of Health and Welfare, Narita/JP
  • 8 Obstetrics And Gynecology, Osaka University, Osaka/JP
  • 9 Obstetrics And Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki/JP
  • 10 Pathology, National Cancer Center Hospital, Tokyo/JP
  • 11 Pathology, Shikoku Cancer Center, 791-0280 - Matusyama/JP
  • 12 Basic Pathology, National Defense Medical College Hospital, Tokorozawa/JP
  • 13 Gynecology Service, National Kyushu Cancer Center, Fukuoka/JP
More

Resources

Abstract 1583

Background

Uterine leiomyosarcomas (uLMSs) are rare and aggressive tumours. Despite complete tumour resection, uLMSs are destined to relapse, and its prognosis is poor. The prognostic factors are not sufficiently known.

Methods

We performed a multi-institutional, retrospective study of women with stage I–IV uLMS, who were diagnosed between 2000 and 2012. For all cases, the histopathological slides of primary lesions were submitted to the central pathological review. Data obtained from medical records included clinicopathological factors, treatment and outcome information.

Results

In total of 259 patients (median age 54 years) were confirmed to have uLMS of which 159 (61%) were stage I, 19 (7%) were stage II, 21 (8%) were stage III, 58 (22%) were stage IV and 2 (1%) were unknown. The median disease-free survival (DFS) period was 18.2 months [95% confidence interval (CI) 13.6–24.1], and the median overall survival (OS) period was 44.2 months [95% CI 32.7–66.2]. Overall, 161 (62%) patients received adjuvant treatment; 155 (60%) received chemotherapy and 8 received radiotherapy. With regard to chemotherapy regimens, 65 (42%) were given docetaxel and gemcitabine; 32 (21%) were given Ifosfamide, doxorubicin and cisplatin; 10 (6%) were administered taxane and carboplatin; 39 (25%) were given other regimens and 9 (6%) were unknown. In a multivariate analysis, stage III–IV disease, high serum lactate dehydrogenase (LDH) level and no adjuvant treatment were significantly associated with shorter median DFS and OS periods. Even in stage I of the disease, high LDH level and no adjuvant treatment were significantly associated with shorter median DFS and OS.

Conclusions

Advanced stage, high LDH level and no adjuvant treatment were associated with poor prognoses. In stage I of the disease, when the tumour was confined to the corpus uteri, postoperative adjuvant chemotherapy was associated with improved survival.

Clinical trial identification

Legal entity responsible for the study

Japanese Gynecologic Oncology Group.

Funding

Eisai, Ono Pharmaceutical Co., Kaken Pharmaceutical Co., Kyowa Hakko Kirin Co., Sanofi K. K., Sawai Pharmaceutical Co., Shionogi & Co., Zeria Pharmaceutical Co., Taiho Pharmaceutical Co., Daiichi Sankyo Company, Chugai Pharmaceutical Co., Nihon Kayaku Co., Bristol-Myers Squibb Company, Yakuly Honsha Co., Janssen Pharmaceutical K.K., Roche Diagnostics K.K., Fuji Pharma Co., Astra Zeneca, ASKA Pharmaceutical Co.

Editorial Acknowledgement

Enago for English language review.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.